在阿尔茨海默氏症 (AD) 患者中,基因组脱乙烯化;希望或作
Nabaa Hisham Ateya1, Sarah F Al-Taie2, Saade Abdalkareem Jasim3
1Biotechnology Department, College of Applied Science, Fallujah University, Al-Fallujah, Iraq.
Cell biochemistry and biophysics
|January 17, 2025
概括
激素脱乙酶 (HDACs) 通过调节激素乙化来减缓阿尔茨海默病的进展,影响记忆基因和认知能力下降. 准HDACs为阿尔茨海默病提供了潜在的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 基因组乙化,由基因组乙转移酶 (HATs) 和基因组脱乙酶 (HDACs) 调节,控制着染色质结构和基因表达.
- 在中枢神经系统 (CNS) 中,基因素乙化对认知和学习相关的基因表达至关重要.
- HDACs在维持基因素乙化平衡方面发挥着关键作用,影响基因可访问性和调节蛋白的功能.
研究的目的:
- 在阿尔茨海默氏病 (AD) 背景下审查HDACs的治疗目标和功能.
- 探索调节HDAC活性如何影响与AD相关的表观遗传机制.
- 突出HDAC抑制剂 (HDACis) 作为AD治疗策略的潜力.
主要方法:
- 审查关于基因素乙化,HDACs以及它们在中枢神经系统功能和神经退行性疾病中的作用的现有文献.
- 对HDACs影响AD中的基因表达,染色质结构和蛋白质聚合的机制的分析.
- 检查HDAC抑制剂对认知过程和AD病理学的影响.
主要成果:
- 在AD中,HDACs降低了与认知衰退,记忆障碍以及粉样蛋白-β (Aβ) 和高酸化的积累相关的基因组乙烯化.
- 抑制HDACs (HDACis) 可以通过增加基因素乙化来逆转其中一些影响,使染色质更容易获得.
- 改变的基因素乙化会影响CBP和Brd4等"读者"蛋白的结合,影响中枢神经系统中的基因转录.
结论:
- 通过表观遗传修饰,HDACs与阿尔茨海默病的进展有关.
- 用抑制剂向HDAC是一种有希望的治疗途径,可以减缓AD的进展.
- 了解HDACs,胰岛素乙化和AD病理之间的相互作用对于开发有效的治疗方法至关重要.
关键词:
阿尔茨海默氏症 (AD) 是一种疾病.粉样蛋白β (Aβ) 是一种蛋白质.希斯脱乙酶 (HDAC) 的使用希斯脱乙酶抑制剂 (HDACi) 的使用神经纤维状结 (NFTs) 是一种神经纤维状结.更多相关视频
08:33Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
Published on: March 24, 2019
7.4K
14:57Preparation of Acute Hippocampal Slices from Rats and Transgenic Mice for the Study of Synaptic Alterations during Aging and Amyloid Pathology
Published on: March 23, 2011
94.0K
相关概念视频
02:32Histone Modification
13.0K
The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...
13.0K
01:26Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
02:25Spreading of Chromatin Modifications
8.2K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.2K
01:22Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160